In 2021, the estimated number of women in the United States living with metastatic breast cancer rose to about 168,000 from 155,000 the year before, according to the Breast Cancer Research Foundation. The good news is that survival rates are also climbing, Over the last 20 years, advances in HER2 targeting treatments, ADCs, immune checkpoint inhibitors, and CDK4/6 inhibitors have prolonged survival and changed the breast cancer treatment landscape. New treatment paradigms and advances invariably lead to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistanceIn this episode we attempt to tackle these questions and review new advances and trends in MBC with assistance from Dr. Stephanie GraffTake a listen. It is going to be an exciting discussion.More info about the show and past episodes is available on our website: www.ourmbclife.orgGot something to share? Feedback? Email: ourmbclife@sharecancersupport.orgFollow us on Facebook, Instagram, and twitter @ourmbclif